Research progress on the effect of Exendin-4 on islet β cells and related mechanisms
LIU Chen#br#
Department of Doctor-patient Relations, Medical Department, the Eighth Affiliated Hospital, Sun Yat-set University, Guangdong Province, Shenzhen 518033, China
Abstract Exendin-4 is a short incretin polypeptide, belonging to a long-acting agonist of glucagon-like peptide-1 (GLP-1) receptor. In recent years, it has been found that Exendin-4 can act on islet β cells in various ways and play a role in the treatment of diabetes. On the one hand, Exendin-4 regulates insulin secretion by specifically binding to GLP-1 receptors on islet β cells. On the other hand, Exendin-4 can also promote the proliferation of islet β cells, regulate autophagy and inhibit apoptosis, and protect islet function. This paper reviews the recent studies on the effects of Exendin-4 on islet β cells and related molecular mechanisms, in order to promote the further application of Exendin-4 in the treatment of diabetes mellitus.
[1] Chan J，Lim LL，Wareham NJ，et al. The Lancet Commission on diabetes： using data to transform diabetes care and patient lives [J]. Lancet，2021，396（10267）：2019-2082.
[2] Saeedi P，Petersohn I，Salpea P，et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045：Results from the International Diabetes Federation Diabetes Atlas，9（th） edition [J]. Diabetes Res Clin Pract，2019，157：107843.
[3] Alavi SE，Ebrahimi SH. GLP-1 peptide analogs for targeting pancreatic beta cells [J]. Drug Discov Today，2021，Online ahead of print.
[4] Eng J，Kleinman WA，Singh L，et al. Isolation and characterization of exendin-4，an exendin-3 analogue，from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas [J]. J Biol Chem，1992，267（11）：7402-7405.
[5] Yap M，Misuan N. Exendin-4 from Heloderma suspectum venom：From discovery to its latest application as type Ⅱ diabetes combatant [J]. Basic Clin Pharmacol Toxicol，2019， 124（5）： 513-527.
[6] Gentilella R，Pechtner V，Corcos A，et al. Glucagon-like peptide-1 receptor agonists in type 2 diabetes treatment： are they all the same? [J]. Diabetes Metab Res Rev，2019， 35（1）：e3070.
[7] Farnsworth NL，Walter R，Piscopio RA，et al. Exendin-4 overcomes cytokine-induced decreases in gap junction coupling via protein kinase A and Epac2 in mouse and human islets [J]. J Physiol，2019，597（2）：431-447.
[8] Yang H，Wang S，Ye Y，et al. GLP-1 preserves β cell function via improvement on islet insulin signaling in high fat diet feeding mice [J]. Neuropeptides，2021，85：102110.
[9] Sun T，Han X. Death versus dedifferentiation：The molecular bases of beta cell mass reduction in type 2 diabetes [J]. Semin Cell Dev Biol，2020，103：76-82.
[10] Gilbert MP，Pratley RE. GLP-1 Analogs and DPP-4 Inhibitors in Type 2 Diabetes Therapy： Review of Head-to-Head Clinical Trials [J]. Front Endocrinol Lausanne，2020， 11：178.
[11] Xie J，El SN，Qi C，et al. Exendin-4 stimulates islet cell replication via the IGF1 receptor activation of mTORC1/S6K1 [J]. J Mol Endocrinol，2014，53（1）： 105-115.
[12] Fusco J，Xiao X，Prasadan K，et al. GLP-1/Exendin-4 induces β-cell proliferation via the epidermal growth factor receptor [J]. Sci Rep，2017，7（1）： 9100.
[13] Xu X，Lai Y，Hua ZC. Apoptosis and apoptotic body： disease message and therapeutic target potentials [J]. Biosci Rep，2019，39（1）：BSR20180992.
[14] Costes S，Bertrand G，Ravier MA. Mechanisms of Beta-Cell Apoptosis in Type 2 Diabetes-Prone Situations and Potential Protection by GLP-1-Based Therapies [J]. Int J Mol Sci，2021，22（10）：5303.
[15] Gu J，Wei Q，Zheng H，et al. Exendin-4 Promotes Survival of Mouse Pancreatic β-Cell Line in Lipotoxic Conditions，through the Extracellular Signal-Related Kinase 1/2 Pathway [J]. J Diabetes Res，2016，2016：5294025.
[16] Madhu D，Khadir A，Hammad M，et al. The GLP-1 analog exendin-4 modulates HSP72 expression and ERK1/2 activity in BTC6 mouse pancreatic cells [J]. Biochim Biophys Acta Proteins Proteom，2020，1868（7）： 140426.
[17] Jiang D，Wan F. Exendin-4 protects INS-1 cells against palmitate-induced apoptosis through the IRE1α-Xbp1 signaling pathway [J]. Exp Ther Med，2018，16（2）：1029-1035.
[18] Xiong L，Gong Y，Wu L，et al. LncRNA-Malat1 is Involved in Lipotoxicity-Induced β-cell Dysfunction and the Therapeutic Effect of Exendin-4 via Ptbp1[J]. Endocrinology，2020，161（7）：bqaa065.
[19] He J，Zhang X，Lian C，et al. Exendin-4 prevented pancreatic beta cells from apoptosis in （Type I） diabetic mouse via keap1-Nrf2 signaling [J]. Exp Biol Med（Maywood），2019，244（1）：28-35.
[20] Mizushima N，Levine B. Autophagy in Human Diseases [J]. N Engl J Med，2020，383（16）：1564-1576.
[21] Lee YH，Kim J，Park K，et al. β-cell autophagy： Mechanism and role in β-cell dysfunction [J]. Mol Metab，2019，27S（Suppl）：S92-S103.
[22] Zummo FP，Krishnanda SI，Georgiou M，et al. Exendin-4 stimulates autophagy in pancreatic β-cells via the RAPGEF/EPAC-Ca（2+）-PPP3/calcineurin-TFEB axis [J]. Autophagy，2021，17（11）：1-17.
[23] Chen X，Huang T，Shi Y，et al. A GLP-1 receptor agonist attenuates human islet amyloid polypeptide-induced autophagy and apoptosis in MIN6 cells [J]. Mol Med Rep，2019，19（2）：1365-1371.
[24] Lim SW，Jin L，Jin J，et al. Effect of Exendin-4 on Autophagy Clearance in Beta Cell of Rats with Tacrolimus-induced Diabetes Mellitus [J]. Sci Rep，2016，6：29921.
[25] Trujillo JM，Nuffer W，Smith BA. GLP-1 receptor agonists： an updated review of head-to-head clinical studies [J]. Ther Adv Endocrinol Metab，2021，12：1904049400.
[26] Bao X，Qian K，Yao P. Oral delivery of exenatide-loaded hybrid zein nanoparticles for stable blood glucose control and β-cell repair of type 2 diabetes mice [J]. J Nanobiotechnology，2020，18（1）：67.
[27] Mietlicki-Baase EG，Liberini CG，Workinger JL，et al. A vitamin B12 conjugate of exendin-4 improves glucose tolerance without associated nausea or hypophagia in rodents [J]. Diabetes Obes Metab，2018，20（5）：1223-1234.
[28] Son S，Park EJ，Kim Y，et al. Chemical chaperone-conjugated exendin-4 as a cytoprotective agent for pancreatic β-cells [J]. Int J Biochem Cell Biol，2018，105：13-19.
[29] Sun L，Huang X，Han J，et al. Site-specific fatty chain-modified exenatide analogs with balanced glucoregulatory activity and prolonged in vivo activity [J]. Biochem Pharmacol，2016，110-111：80-91.
[30] Lin JY，Cheng J，Du YQ，et al. In vitro expansion of pancreatic islet clusters facilitated by hormones and chemicals [J]. Cell Discov，2020，6：20.
[31] Song X，Sun X，Hao H，et al. Combined Treatment with Bone Marrow-Derived Mesenchymal Stem Cells and Exendin-4 Promotes Islet Regeneration in Streptozotocin-Induced Diabetic Rats [J]. Stem Cells Dev，2021，30（9）：502-514.
